RxDoctor Payments Data

Joseph Lewcun, DO

Family Medicine · Dresher, PANPI 1457463648

Payments from drug & device makers

$12,189in general payments, 2019–2025

Across 596 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$771
  • Abbott$634
  • Merck$464
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$12,04699%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,189 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$74,286
Medicare patients
203
Services billed
772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$53,597
JardianceEmpagliflozin35$33,813
EliquisApixaban20$24,599
VraylarCariprazine Hcl17$24,178
TrulicityDulaglutide16$14,059
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,371
JanumetSitagliptin Phos/Metformin Hcl15$10,568
VascepaIcosapent Ethyl11$8,082
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$3,106
Rosuvastatin Calcium169$3,020
Atorvastatin Calcium228$2,676
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp17$2,670
Albuterol Sulfate HfaAlbuterol Sulfate83$2,248
SynthroidLevothyroxine Sodium32$2,066
Levothyroxine Sodium158$1,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,154$53,59748 claims
Boehringer IngelheimJardiance$113$33,81335 claims
AbbVieVraylar, Synthroid$3,422$26,24449 claims
PfizerEliquis$331$24,59920 claims
Lilly USA, LLCTrulicity$771$14,05916 claims
GSKTrelegy Ellipta$43$11,37112 claims
MerckJanumet$464$10,56815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Dresher

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →